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Abstract
Background: Gastric cancer is one of the major causes of cancer-related mortality worldwide. Most of patients
presenting with inoperable gastric cancers rely on systemic chemotherapy for prolongation of survival. Doxorubicin
(DOX) is one of the important agents against gastric cancer. Acquired DOX-resistance severely impedes the
chemotherapeutic effect, invariably leading to poor prognosis. Resveratrol (RES) as a kind of phytoalexin has
demonstrated anti-tumor functions in breast cancer and myeloid leukemia, but its function and mechanism are
still unknown in gastric cancer treatment.
Methods: CCK8 assay was used to detect the cytotoxicity of DOX and RES to gastric cancer cells. DOX-resistant
subclone cell line (SGC7901/DOX) was derived from SGC7901 cells exposed to stepwise increasing concentrations
of DOX treatment. We measured the migratory capabilities of SGC7901/DOX cells by Cell scratch test and Transwell
assay. SGC7901/DOX cells were treated with DOX, RES, neither or both. Then we analyzed cell survival by CCK8
assay, colony formation by Colony-forming assay, cell apoptosis by Annexin-V-FITC and PI dual staining assay and
cell migration by Cell scratch test and Transwell assay. Western blotting was conducted to detect the protein
expressions of PTEN/Akt signaling pathway and EMT-related markers. Immunofluorescence was performed to
confirm the EMT-related markers expressions. The xenograft model was used to assess the effect of DOX and RES in
vivo. The key molecules associated with proliferation, apoptosis and EMT were evaluated by immunohistochemistry
in tumor specimens.
Results: SGC7901/DOX cells acquired drug resistance and enhancive migratory capability. RES enabled SGC7901/
DOX cells to regain DOX sensitivity, mitigated the aggressive biological features, promoted cell apoptosis in vitro
and inhibited tumor growth in vivo. Mechanistic studies revealed that SGC7901/DOX cells underwent epithelial-
mesenchymal transition (EMT) which was induced by Akt activation, and through activating PTEN, RES inhibited
the Akt pathway, and then achieved the reversion of EMT.
Conclusion: RES serves as a novel solution to reverse the DOX-resistance of gastric cancer via preventing EMT by
modulating PTEN/Akt signaling pathway. DOX-RES combined treatment provides a promising future for gastric
cancer patients to postpone drug resistance and prolong survival.
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Background
Gastric cancer is the fourth common malignancy in males
and the fifth in females. It accounts for about 9% of world-
wide cancer deaths in 2012 [1]. Most newly diagnosed
cases present with locally advanced or metastatic gastric
cancers [2, 3] Still those patients with operable gastric
adenocarcinoma would have a high risk of recurrence
after tumor complete resection despite improvements in
the surgical treatment [4]. Chemotherapy has long been
considered as a sophisticated treatment of locally ad-
vanced and metastatic gastric cancers [5, 6]. Doxorubicin
(DOX), an anthracycline-based anti-tumor drug combined
with other chemotherapeutic agents including fluorouracil
and mitomycin, was first introduced as a gold therapy
regimen for advanced gastric cancer patients in 1980
[7]. However, some clinical trials reported traditional
DOX-based regimens failed to prolong survival and
brought about some adverse effects for gastric cancer
patients [8–11]. Recent in vitro study indicated that the
frequent acquisition of DOX resistance and the potential
induction of epithelial–mesenchymal transition (EMT)
might be crucial in the limitation of DOX treatment in
gastric cancer [12]. To find out a novel solution to allevi-
ate the adverse effects in an all-round way, we endeavor to
discover a chemo-sensitizer and side-effects attenuator for
DOX in gastric cancer chemotherapy as well as its mo-
lecular mechanism.
A number of phytochemicals available exhibit chemo-
preventive effect and sensitize cancer cells toward DOX
[13]. Among various phytochemicals, resveratrol (RES),
a self-protective polyphenolic phytoalexin derived from
plants, has attracted increasing attention due to its mul-
tiple health benefits [14]. In addition to the pharmaco-
logical effects of RES on the aging process, diabetes,
neurological dysfunction, cardiovascular system and in-
flammation, its potent anti-tumor activity were closely
observed in studies including breast cancer, lung cancer,
prostate cancer, hepatocaracinoma, colorectal cancer and
so on [14–16]. The combined treatment of DOX and RES
achieves a synergistic effect and reverses multidrug-
resistance in breast cancer cells [17] and acute myeloid
cells [18]. As DOX is one of the key chemotherapy agents
in gastric cancer treatment, the combination of DOX and
RES turns out to be a potentially promising chemotherapy
regimen for gastric cancer and the relevant mechanism re-
mains to be explored.
In this study, DOX-resistant human gastric cancer cell
line (SGC7901/DOX) was established and demonstrated
aggressive migratory capabilities. Then RES was intro-
duced and it successfully alleviated cell migration and
chemo-sensitized DOX through reversing EMT process
and regulating PTEN and Akt/mTOR pathway. Our work
sheds new light on RES as a potential adjuvant to DOX in
gastric cancer treatment to solve drug resistance and
tumor metastasis. And the relevant mechanism study and
prospective clinical trials are expected.
Methods
Cell culture
Human gastric cancer cells SGC7901 and MGC803
were obtained from American Type Culture Collection
Cell Biology Collection (ATCC, Manassas, VA, USA)
and maintained in Department of Pathology, Southern
Medical University (Guangzhou, China). Cells were cul-
tured in RPMI 1640 medium supplemented with 10% fetal
bovine serum (FBS) at 37 °C in a humidified incubator
containing 5% CO2.
Establishment of DOX-resistant gastric cancer cell line
The DOX concentration gradient progressive increase
induction method was used to develop DOX-resistant
phenotype SGC7901 cell line. SGC7901 cells at a con-
centration of 1 × 105/ml were inoculated in DOX-free
culture medium for 24 h until they got in the logarith-
mic phase. Then the culture medium was replaced with
that containing low concentration (0.125 mg/L) DOX
(Nanfang Hospital, Guangzhou, China, dissolved in
RPMI 1640 medium) for 48 h. Then the culture medium
containing drugs and dead cells was discarded. Cells
were collected and re-inoculated in DOX-free culture
medium to get recovered before next DOX treatment.
After cells got adjusted to present DOX treatment, we
increased the concentration of DOX and repeated the
DOX and DOX-free treatment in turn until cells survived
well and developed resistance to 0.75 mg/L DOX treat-
ment. We referred to this DOX-resistant SGC7901 cell
line as SGC7901/DOX. Both DOX- sensitive SGC7901
and DOX-resistant SGC7901/DOX were cultured under
the same conditions and in drug-free medium for 2 days
before commencing the experiments.
CCK-8 assay
Cell survival rates were estimated by the CCK-8 assay
(keyGEN biotech, Jiangsu, China). Approximately 104
cells were seeded in 96-well plates with 100 μl medium
each well. After 24 h cultivation, different doses of DOX
or/and RES were added respectively. Each well was
incubated with 10 μg CCK-8 solution for 2 h away from
light before measuring the absorbance at 450 nm by
PerkinElmer’s EnSpire Multilabel Plate Reader.
Cell scratch test
When the cells seeded in 6-well plate reached a conflu-
ent state, a single scratch was made using a sterile
10 μl pipette tip. The cells were then incubated with
FBS-free culture medium (to exclude the potential
effects of FBS on cell migration) alone or containing
different concentrations of DOX or RES (SinaBestBio,
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Shanghai, China, dissolved in 10% DMSO (DMSO:RPMI
1640 medium= 1:9)). Images of the scratches were
captured at 0, 24 and 48 h with Olympus IX71 inverted
microscope at 100× magnification. The width of the
scratch was analyzed using the Olympus CellSens Dimen-
sion software.
Transwell migration assay
Transwell migration assay was performed using transwell
inserts (BD bioscience, SanJose, CA) with a filter of 8 μm
pore. Cells were left untreated or treated with DOX, RES
or both for 48 h. 8 × 104 cells in serum-free medium were
seeded into the upper chamber of the insert and complete
medium was added to the lower chamber. After 36 h incu-
bation, the cells were fixed with methanol and stained
with Giemsa. Then cells on the top surface of the mem-
brane were wiped off, and cells on the lower surface were
examined with Olympus DP72 microscope at 100× mag-
nification. 4 random fields were photographed for count-
ing purposes and the average number of migrated cells
was used as a measure of migration capacity.
Colony-forming assay
Cells were left untreated or treated with DOX, RES or
both for 48 h. Then cells were trypsinized and dispensed
into individual wells of six-well tissue culture dishes with
a density of 300 cells per well. Following another 14 days
in drug-free culture, cells were fixed and stained with
Giemsa to visualize colonies. Experiments were performed
in triplicate.
Apoptosis analysis
To detect cell apoptosis, cells were incubated with DOX
or RES at different concentrations for 24 h. About 1 × 105
cells were harvested by EDTA-free trypsinization and
washed twice with cold PBS. After being resuspended in
500 μL binding buffer, cells were stained with 5 μL
Annexin-V-FITC and 5 μL PI (Keygen bioTECH, Jiangsu,
China) in dark condition at room temperature for 15 min.
Lastly, cell apoptosis was measured by FACSAria flow cyt-
ometer (BD, USA).
Immunofluorescence
The cells seeded in co focal dishes were fixed with 4%
paraformaldehyde and then kept stable in 0.2% Triton
for 10 min to rupture the cell membranes. Following
three PBS washing, non-specific antigen-binding sites
were blocked by 2% BSA for 30 min. The cells were
then incubated with anti- Vimentin, E-cadherin (Abcam,
1:200); anti-β-catenin (Proteintech, 1:50) overnight at 4 °C.
After washing, cells were incubated with anti-rabbit anti-
body for 60 min and the nuclei were stained with DAPI for
2 min, which was washed with PBS later. Cells were kept
from light before observed with a fluorescence microscope.
Western blot analysis
Cells to be tested were homogenized in Lysis Buffer (con-
taining 0.1% protease inhibitor, 0.5% 100 mM PMSF and
1% phosphatase inhibitor) and centrifuged at 12,000 rpm
for 15 min at 4 °C. The supernatant was collected and the
total protein content was determined by BCA assay. Equal
proteins (40 μg/lane) were loaded on SDS-PAGE gels and
then transferred to 0.22 μm PVDF membranes. Mem-
branes were blocked with 5% fat-free milk (5% skimmed
milk powder in PBST, 0.1% Tween in PBS) and incubated
with primary antibodies overnight at 4 °C. After being
washed by PBST for 5 × 5 min, membranes were incu-
bated with secondary antibodies for 1 h at room
temperature. Following washing, target bands were vi-
sualized using Tanon-5200 Image Analyzer.
Primary antibodies used included rabbit monoclonal
antibodies anti- PTEN, Akt, phosphor-Akt, mTOR,
phosphor-mTOR, TSC1, TSC2, p70S6K, β-catenin,
cleaved caspase-3 and caspase-9 (1:500, Cell Signaling
Technology, Danvers, MA); rabbit monoclonal antibodies
anti- Vimentin, E-cadherin (1:500, Abcam, Cambridge,
UK); mouse monoclonal antibody anti-GAPDH (1:500,
Proteintech, Chicago, IL). Protein bands were quantified
using the Tanon-5200 Image Analyzer. All bands were
normalized to GAPDH and the fold changes were
calculated through relative quantification to the con-
trol group.
Nude mice xenograft model
Nude mice were purchased from Guangdong Medical
Laboratory Animal Center (Guangzhou, China) and
housed under controlled temperature (28 °C) and
pathogen-free conditions at Guangdong Provincial Key
Laboratory of Molecular Tumor Pathology. All proce-
dures were performed aseptically in accordance with
the institutional guidelines of Guangdong Province and
approved by the Experimental Animal Ethics Commit-
tee of Southern Medical University. 1 × 107 SGC7901/
DOX cells were injected subcutaneously into the left
inguinal region of each nude mouse when the mice got
five weeks old. Two weeks later, mice were randomly
divided into four groups (n = 5, 3 males, 2 females):
Group 1 Control; Group 2 DOX (3 mg/kg); Group 3
RES (50 mg/kg); Group 4DOX (3 mg/kg) and RES
(50 mg/kg). DOX was diluted in sodium chloride injec-
tion and given intraperitoneally (i.p.) while RES was
dissolved in 10% DMSO and administered by gavage.
Both drugs were given once a week for 4 consecutive
weeks. The tumor volume (V) was determined by
measuring the length (a) and width (b) with calipers
every week and calculated using the formula: V (mm3)
=1/2*ab2. At the end of the treatment period, mice were
sacrificed, and tumors were collected for immuno-
chemical studies.
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Immunohistochemistry
The tumor tissue was fixed with 4% formalin and paraf-
fin embedded before cutting it into 3 μm thick sections.
And the sections were routinely deparaffinized in xylene
and rehydrated in an alcohol gradient. Next, tissue anti-
gen was retrieved by heating in sodium citrate (pH 6.0)
or Tris-EDTA solution (pH 8.0) for 10 min. Sections
were then blocked with 3% H2O2 before incubation with
anti- caspase-3 (Cell Signaling Technology, 1:200); anti-
ki67 (Cell Signaling Technology, 1:400); anti- Vimentin
(Abcam, 1:500); anti-PTEN (Proteintech, 1:200) at 4 °C
overnight. After three washes in PBS, the sections were in-
cubated with secondary antibody (ZSGB-BIO, Beijing,
China) for 30 min at room temperature. DAB kit (ZSGB-
BIO, Beijing, China) was sequentially applied to stain the
slides. Following counter-staining in hematoxylin and
mounting with neutral balsam, the tissue sections were
observed using Olympus BX-UCB light-field microscope.
5 random fields at × 400 magnification were captured for
intensity analysis.
We used Image-Pro Plus software for semi-quantitative
Image analysis. Firstly, we opened the image in the soft-
ware and calibrated the optical density. In Measure menu
we clicked Count/Size and chose Manual to enter into
Segmentation dialogue box where the area of interest was
set through: hue, 0 ~ 30; saturation, 0 ~ 255; intensity,
0 ~ 255, then the image was converted to gray scale
image. Subsequently, we returned to Count/Size window,
clicked Count and the values were measured. The param-
eters included area sum and IOD. The mean optical
density was calculated by IOD/area and designated as rep-
resentative staining intensity [19, 20].
Statistical analysis
Data were expressed as means ± SD of at least three in-
dependent experiments. Statistical evaluation of the data
was performed by using the unpaired Student’s t-test
and ANOVA followed by a post-hoc test. Differences
were considered to be statistically significant for p <
0.05. Statistical analysis was performed by SPSS 19.0
software.
Results
The effects of DOX and RES on gastric cancer cells
We detected the chemo-sensibility of SGC7901 and
MGC803 to DOX and RES treatment via CCK8 assay.
The DOX concentration gradient ranges from 0.5 mg/L
to 10 mg/L. Results showed SGC7901 cell survival was
inhibited by DOX and the inhibition rate was increased
with DOX treatment time and concentration. However,
DOX did not suppress MGC803 cell survival in a dose
and time-dependent way until its concentration was over
2 mg/L. Particularly, MGC803 survival rate could reach
as high as 40% after 7-day treatment of 0.5 mg/L DOX
(Fig. 1a). The RES concentration gradient ranges from
10 mg/L to 200 mg/L. Results showed that RES also
significantly inhibited SGC7901 cell survival dose and
time-dependently within the concentration range set.
However, RES did not suppress MGC803 cell survival in a
dose and time-dependent way until its concentration was
over 20 mg/L (Fig. 1b). The 7-day survival of MGC803
maintained over 80% when treated with 10 mg/L RES and
about 60% in 20 mg/L RES.
Drug-resistant SGC7901/DOX cells were established and
demonstrated enhancive migratory phenotype
Overall, DOX and RES demonstrated similar effects on
the survival of both gastric cancer cell lines. But compared
with MGC803, SGC7901 was more sensitive to both
drugs, which made it a proper subject of our further study.
The half maximal inhibitory concentration (IC50) of DOX
in day2 for SGC7901 was 0.7635 mg/L (with 95% confi-
dential interval 0.6765 to 0.8617 mg/L).
DOX-resistant subclone cell line (SGC7901/DOX) was
derived from SGC7901 cells exposed to stepwise in-
creasing concentrations (0.125 mg/L to 0.75 mg/L) of
DOX treatment. To verify the DOX-resistant difference
between SGC7901 and SGC7901/DOX cells, we treated
both cell lines with different concentrations of DOX for
2 days and then measured the half maximal inhibitory
concentration (IC50). The IC50 of parental SGC7901
cell line was 0.7173 mg/L, and its 95% confidential interval
(CI) was 0.6415 to 0.8019 mg/L while that of SGC7901/
DOX cell line was 2.959 mg/L with a 95% CI ranging from
2.554 to 3.428 mg/L. The results showed that SGC7901/
DOX cells were more DOX-resistant in comparison to its
parental SGC7901 cells for its IC50 was 316% greater than
that of SGC7901 (Fig. 2a).
Cell migration was analyzed by cell scratch test and
transwell assay. Cell scratch test confirmed the migra-
tion potential of SGC7901/DOX (147.91 ± 4.32 μm) cells
was 44.27% greater than that of SGC7901 cells (102.52
± 4.72 μm, p < 0.001) (Fig. 2b). Transwell assay also
reported SGC7901/DOX cells acquired enhancive cell
migratory ability than parental SGC7901 cells, which
was evidenced by increased number of trans-membrane
migrating cells by 90.53% (700.40 ± 22.38 SGC7901/
DOX cells compared with 367.60 ± 5.07 SGC7901 cells
(p < 0.01) (Fig. 2c).
SGC7901/DOX cells underwent EMT associated with Akt
activation
EMT has been illustrated as a critical regulator in cell mi-
gration and drug resistance. Morphological observation
showed that the parental SGC7901 cells were generally
round or oval, but most of SGC7901/DOX cells trans-
formed into spindle shape (Fig. 3a). The expression of
EMT associated markers was measured by western blot.
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SGC7901/DOX cells were found to undergo EMT
process for it expressed higher mesenchymal cell
markers including β-catenin and vimentin while losing
epithelial cell adhesion molecule such as E-cadherin. In
addition, Akt was activated in SGC7901/DOX cells
(Fig. 3b). EMT markers were also verified through im-
munofluorescent assay. Long-term DOX incubation de-
creased E-cadherin cytomembrane expression whereas
increased vimentin expression in cytoplasm and enhanced
β-catenin nuclear tranlocation (Fig. 3c).
RES alleviated the aggressive phenotypes of SGC7901/
DOX cells
To evaluate the cytotoxic effect of RES on SGC7901/DOX
cells, cells were treated with 0.75 mg/L DOX or 50 mg/L
RES, either alone or in combination. CCK8 assay results
showed DOX (0.75 mg/L) had no significant effect on the
survival of SGC7901/DOX cells, which indicated that
SGC7901/DOX cells maintained DOX-resistant feature as
previously described. As for the RES group, RES treatment
displayed a time-dependent inhibitory effect on SGC7901/
DOX cell survival. Notably, when DOX was combined
with RES, the survival rate of SGC7901/DOX cells was
minimized (Fig. 4a).
Furthermore, we analyzed whether the combined
treatment could suppress the colony-forming ability of
SGC7901/DOX cells. DOX and RES treatment de-
creased the number of SGC7901/DOX cell colonies by
only 33.95 and 76.54% respectively. When DOX and
RES were combined, the colony forming ability of
SGC7901/DOX cells reached the lowest point, much
lower than either treatment alone (Fig. 4b).
Also, the effect of RES and/or DOX on cell apoptosis
was measured. DOX treatment alone could induce
SGC7901/DOX cell apoptosis, but it was not prominent
at low concentrations (1 mg/L and 1.5 mg/L). RES alone
triggered cell apoptosis in a concentration-dependent
manner, with 8.7% apoptotic cells resulting in 50 mg/L
treatment and then 26.5% in 100 mg/L. Altogether,
1 mg/L DOX and 50 mg/L RES combined treatment
Fig. 1 The effects of DOX and RES on gastric cancer cells. a CCK8 assay was used to detect the chemo-sensitiviy of SGC7901 and MGC803 cells to
DOX treatment. Survival rate = (mean absorbance of experimental group/mean absorbance of control group) × 100%. The survival inhibition effect of
doxorubicin demonstrated a dose (Factorial ANOVA, p < 0.001) and time-dependent (Factorial ANOVA, p < 0.001) manner, except that the difference
between 10 mg/L and 5 mg/L (p = 0.910) and that between day 4 and day 5 (p = 0.300) were not significant. b The reveratrol concentration gradient
ranges from 10 mg/L to 200 mg/L. The survival inhibition effect of resveratrol on SGC7901 cells demonstrated a dose (Factorial ANOVA, p < 0.001) and
time-dependent (Factorial ANOVA, p < 0.001) manner. Also, the survival inhibition effect of resveratrol on MGC803 cells demonstrated a dose (Factorial
ANOVA, p < 0.001) and time-dependent (Factorial ANOVA, p < 0.001) manner when resveratrol concentration was over 20 mg/L
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synergistically promoted cell apoptosis proportion up to
29.2% (Fig. 4c). The results revealed that RES increased
the DOX-sensibility of SGC7901/DOX cells by synergiz-
ing DOX’s function in inhibiting cell proliferation and
promoting cell apoptosis.
The effect of RES on SGC7901/DOX cell migration was
also investigated. To our surprise, cell scratch test sug-
gested that DOX treatment alone promoted the migration
of SGC7901/DOX cells by 25.9% whereas RES decreased
that of SGC7901/DOX by 53.13%. Notably, combination
of DOX and RES achieved a remarkably stronger
migration-inhibitory effect than RES or DOX treatment
alone (Fig. 4d). According to transwell assay results, after
48 h DOX treatment, the number of trans-membrane
SGC7901/DOX cells was increased by 31.64%. However,
RES, whether alone or combined with DOX, drastically
decreased migrating cell number (Fig. 4e). Therefore, RES
effectively prohibited SGC7901/DOX cells migration and
what’s more, it significantly antagonized and reversed
SGC7901/DOX cells migration when DOX was present.
RES combined with DOX could reverse EMT
To verify the migration-inhibitory effect of RES was asso-
ciated with the mitigation or even reversion of EMT, mor-
phological changes among SGC7901/DOX cells treated
with DOX, RES or both for 48 h were captured.
SGC7901/DOX cells, no matter treated with DOX or not,
demonstrated spindle or shuttle shapes, but they turned
round or oval when RES was present (Fig. 5a).
Then the expression of EMT-related proteins was
detected by western blot and immunofluorescent assay
for further verification. Similar to our previous findings
in long-term DOX treated SGC7901/DOX cells, 48-h
DOX treatment on SGC7901/DOX cells enhanced the
Fig. 2 Drug-resistant SGC7901/DOX cells were established and demonstrated enhancive migratory phenotype. a CCK8 assay was used to evaluate the
chemo-sensitiviy of SGC7901 cells and SGC7901/DOX cells to different concentrations of DOX after 48-h treatment (n = 4, **P < 0.001, *P < 0.01). b Cell
scratch test was performed to measure the migration ability of SGC7901 and SGC7901/DOX cells. The Scale bar represents 100 μm. The data are
represented as mean ± SD of four independent experiments (n = 4, *** p < 0.001). c Representative photographs of transwell migration assay and the
number of transmembrane cells. The Scale bar represents 100 μm. Data represent as mean ± SD of four independent experiments (n = 4, *** p < 0.001)
Xu et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:19 Page 6 of 14
expression of mesenchymal cell markers such as vimen-
tin and β-catenin, and reduced that of E-cadherin, an
epithelial cell adhesion molecule. RES treatment, whether
combined with DOX or not, decreased the expression of
vimentin and increased E-cadherin expression dominantly,
but had not significantly changed that of β-catenin
when treated alone. However, when DOX was present,
RES significantly antagonized DOX-induced upregulation
Fig. 3 SGC7901/DOX cells underwent EMT mediated by upregulation of Akt signaling pathway. a Images were captured by Olympus IX71
inverted microscope system. Morphological observation showed morphological variance between SGC7901/DOX and SGC7901 cells. The Scale
bar represents 10 μm. b SGC7901 and SGC7901/DOX cells were left DOX-untreated for 48 h for Western blot assay, measeuring EMT-related
proteins and Akt expression. Bar diagram shows the relative expressions of proteins normalized to GAPDH. Data are represented as mean ± SD of
three independent experiments (n = 3, *** p < 0.001; ** p < 0.01; * p < 0.05: NS means not significant, p > 0.05). c Immunofluorescence assay was
used to detect EMT-associated proteins in SGC7901/DOX cells. E-cadherin, β-catenin, and vimentin were stained red and nuclei stained with DAPI
were blue. The white arrow indicates β-catenin nuclear tranlocation. Images were captured at 1800× magnification
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of β-catenin. And compared with either treatment alone,
vimentin expression was significantly downregulated in
DOX-RES combined treatment cells (Fig. 5b), which was
consistent with its cell migration suppressing effect. More-
over, the downregulation of vimentin expression on com-
bined treatment cells was intensified as RES concentration
increased (Fig. 5c). Similar cellular changes of E-cadherin,
β-catenin and vimentin expression were verified in im-
munofluorescent assay (Fig. 5d). These studies showed
that RES antagonized DOX-induced EMT through the
downregulation of vimentin and β-catenin, and upregula-
tion of E-cadherin.
RES modulated PTEN/Akt signaling pathway in SGC7901/
DOX cells
To gain insight into the molecular mechanism through
which RES reversed EMT, the expression of PTEN/Akt
signaling pathway was analyzed by western blot. Results
indicated that 1 mg/L DOX treatment alone did not
affect PTEN expression significantly. Along with the com-
bination of 1 mg/L DOX, however, RES significantly
activated PTEN expression and prohibited Akt phosphor-
ylation as its concentration increased from 20 mg/L to
200 mg/L. Moreover, the expression of cleaved caspase-9
was also enhanced in a RES-dependent way when RES
Fig. 4 RES synergized DOX effect on cell proliferation, colony formation and apoptosis and resvered DOX-induced cell migration in SGC7901/
DOX cells. a CCK8 was used to detect the cytotoxicity of DOX, RES or both. SGC7901/DOX cells were left untreated or treated with 0.75 mg/L
DOX, 50 mg/L RES or both for 7 days. Each data point represents a mean value of four experiments and the error bars indicate the standard
deviation (T test, vs. DOX + RES, *, p < 0.01; **, p < 0.001, n = 4). b Representative pictures of Colony-forming assay and number of cell colonies.
After 48 h’ exposure to DOX or RES or both, the colony forming abilitiy of SGC7901/DOX cells was tested. (n = 3, *** p < 0.001; *, p < 0.05). c SGC7901/
DOX cells were treated with 1 mg/L DOX, 1.5 mg/L DOX, 50 mg/L RES, 100 mg/L RES or 0.75 mg/L DOX combined with 50 mg/L RES respectively for
48 h. Annexin V-FITC/PI dual staining apoptosis analysis was performed. The proportions of cells in each quadrant are marked on the figures. d The
migration distance was meaured to analysed the migration ability of SGC7901/DOX cells which were left untreated or treated with 1 mg/L DOX,
50 mg/L RES or both for 48 h. The Scale bar represents 100 μm. The migration distance of each group was measured, with 162.89 ± 11.20 μm,
205.11 ± 6.79 μm, 76.34 ± 6.16 μm, 24.36 ± 4.83 μm for control, DOX, RES and DOX + RES group. (n = 4, *** p < 0.001;**p < 0.01). e SGC7901/
DOX cells were left untreated or treated with 1 mg/L DOX, 50 mg/L RES or 1 mg/L DOX simultaneously combined with 50 mg/l RES for 48 h.
Then cells were subjected to transwell migration assay. The Scale bar represents 100 μm. The numbers of cells of the control, DOX, RES and
DOX + RES groups were 700.40 ± 50.03, 922.00 ± 53.25, 271.60 ± 20.07 and 116.00 ± 6.50 respectively (n = 4, *** p < 0.001;**p < 0.01)
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Fig. 5 Effect of RES on DOX-induced EMT. SGC7901/DOX cells were untreated or treated with 1 mg/l DOX, 50 mg/l RES or 1 mg/l DOX simultaneously
combined with 50 mg/l RES for 48 h. a Representative images of treated cells were shown. Scale bar represents 10 μm. b, c After 48 h treatment, cells
were harvested for Western blot analysis to detect whether DOX and RES affect the expression of EMT-related proteins. Bar diagram shows the relative
expressions of proteins normalized to GAPDH. Data are represented as mean ± SD of three independent (n = 3, *** p < 0.001; ** p < 0.01; * p < 0.05: NS
means not significant, p > 0.05). d Immunofluorescence assay was used to detect EMT-related proteins. Vimentin, E-cadherin and β-catenin
were stained red and nuclei stained with DAPI were blue. The white arrow indicates β-catenin nuclear tranlocation. Images were captured at
1800× magnification
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concentration ranged from 50 mg/L to 200 mg/L (Fig. 6a).
To detect whether RES modulates PTEN/Akt signaling
pathway as a whole, we treated SGC7901/DOX cells
with 1 mg/L DOX, 50 mg/L RES or both. Consistant
with previous observation, in 50 mg/L RES treatment
group, we saw an significant increase in the level of
PTEN, TSC1, TSC2 and cleaved caspase-3 and a reduc-
tion in p-Akt, p-mTOR and p70 S6K. Notably, when
RES was combined with DOX, PTEN upregulation and
caspase-3 cleavage were strengthened in comparison to
RES treatment alone (Fig. 6b). This study verified that
RES suppressed Akt signaling pathway by upregulating
PTEN.
RES and DOX combination synergistically delayed tumor
growth through reverse of EMT and promotion of
apoptosis by activating PTEN in vivo
To evaluate the effect of DOX and RES on tumor growth,
nude mice bearing subcutaneous SGC7901/DOX xeno-
grapfts (with mean tumor volume 36.46 ± 13.82 mm3)
were given DOX, RES or both for 4 consecutive weeks.
Administration of DOX (3 mg/kg) reduced the tumor
volume by 50.44%, from 1387.10 ± 248.02 mm3 of Control
to 687.45 ± 69.69 mm3 (p < 0.001), and RES (50 mg/kg)
reduced the tumor volume by 58.42% to 576.80 ±
110.64 mm3 (p < 0.001). And likewise, the novel regimen
of combinatorial treatment achieved a synergistic tumor-
Fig. 6 Effect of RES on PTEN/Akt signaling pathway in SGC7901/DOX cells. a, b Following 48 h treatment, SGC7901/DOX cells were harvested for
Western blot analysis to evaluate the effect of DOX and RES on PTEN/Akt signaling expression. Bar diagram shows the relative expressions of
proteins normalized to GAPDH. Data are represented as mean ± SD of three independent (n = 3, *** p < 0.001; ** p < 0.01; * p < 0.05: NS means
not significant, p > 0.05)
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inhibitory effect, minimizing the tumor volume by
86.97% to 180.75 ± 119.38 mm3 (p < 0.001), which was
73.71% (p < 0.001) and 68.66% (p < 0.001) lower than
DOX and RES treatment respectively (Fig. 7a).
To further validate the molecular basis, we then per-
formed immunohischemistry on the tumor xenografts to
detect the level of proliferation marker Ki67, EMT-related
vimentin, apoptosis-related caspase 3 and the Akt signal-
ing inhibitor PTEN in vivo. As expected, DOX alone did
not affect PTEN expression, but significantly increased
the expression of vimentin and caspase-3 and reduced
Ki67 expression. Compared with control group, RES alone
evidently enhanced PTEN and caspase-3 expressions
while reducing Ki67 and vimentin expressions. Moreover,
when combined with DOX, RES achieved a much more
dramatic enhancive effect on PTEN and caspase-3, and
displayed a more remarkable inhibitory effect on vimentin
and Ki67 (Fig. 7b).
Discussion
Chemotherapy, which provides palliation of symptoms
and improves survival and life quality, is the most effective
treatment for patients with inoperable cancers. However,
conventional DOX-based chemotherapy regimen has been
criticized for a series of negative effects, including the
development of drug resistance and the occurrence of
Epithelial–mesenchymal transition (EMT) [21, 22].
EMT not only enhances the metastatic potentials of
cancer but also participates in the development of
chemo-resistance [23, 24]. EMT is the physiological or
pathological conversion of epithelial cells to mesenchy-
mal cells, in which cells undergo phenotypic changes
including the loss of cell polarity and cell-cell adhesion,
the acquisition of migratory and invasive properties,
which are highly responsible for carcinoma progression.
The EMT-induced stemness endows cancer cells with the
ability to overexpress chemo-resistance related genes,
leading to multiple drug resistance in cancer treatment
[25]. A previous study detected DOX-induced EMT in
BGC823 gastric cancer cells. Inhibition of β-catenin sig-
naling could suppress DOX-induced EMT and cell migra-
tion [22]. Suppression of EMT through selective
inhibition of β-catenin signaling could restore sensitivity
to HER-2 targeted lapatinib in HER-2 positive gastric can-
cer cells SNU216 cells [26]. Very recently, an EMT
lineage-tracing system was established to monitor revers-
ible and transient EMT process in mice. Upon treatment
with cancer chemotherapy drug cyclophosphamide,
EMT cells were detected in the primary tumor and
showed chemo-resistance owing to reduced prolifera-
tion, apoptotic tolerance and increased expression of
chemoresistance-related genes. Theses EMT cells also
contributed to recurrent lung metastasis formation
after chemotherapy. These data suggested that EMT
plays an important role in cancer drug resistance and
contributes to metastasis after chemotherapy treatment
[27]. In our study, we generated SGC7901/DOX cell
line by long-term and incremental DOX treatment,
which was characterized by the acquisition of drug re-
sistance and enhancive migration (Fig. 2). And mean-
while, SGC7901/DOX cells displayed an apparent EMT
potential for they were transformed into spindle-like
shape, and expressed high level of mesenchymal cell
markers including β-catenin and vimentin while losing
epithelial cell adhesion molecule such as E-cadherin
(Fig. 3).
EMT-mediated therapeutic resistance in solid tumors is
regulated by many canonical signaling pathways, among
which PI3K/Akt is of high interest. [28, 29] PI3K phos-
phorylates PIP2 into PIP3, which then phosphorylates Akt
in turn. Akt gets activated by phosphorylation of its
Ser473 residue and stimulates the mTOR complex 1
(mTORC1) by phosphorylating tuberous sclerosis com-
plex2 (TSC2) and subsequently inhibiting TSC1/2 com-
plex formation, which is a negative regulator of mTORC1.
Further, the mTORC1 complex acts on RHEB (Ras homo-
log enriched in brain) to phosphorylate mTOR at Ser2448
and thus resulting in mTOR activation. Then mTOR
regulates protein translation and cell growth by phosphor-
ylating ribosomal S6 kinase (p70S6K) [30]. It has been
reported that mTOR inhibitors decrease p70S6K and re-
verse resistance to DOX [31]. Another important sub-
strate of Akt that initiates the mitochondrial apoptotic
pathway is caspase-9, which is inactivated by Akt
through the phosphorylation at Ser196 [32]. Caspase-9
inactivation then leads to the downregulation of
caspase-3 and suppression of caspase-dependent apop-
tosis [33]. As other study shows, Akt activation induces
cancer cell invasiveness partially through interaction
with vimentin. The binding of Akt to vimentin en-
hances the ability of vimentin to induce motility and in-
vasion while protecting vimentin from caspase-induced
proteolysis [34]. Vimentin promotes cell invasiveness
via the regulation of E-cadherin/β-catenin complex.
[35] Compared with E-cadherin and β-catenin, vimen-
tin seemed to be a more specific and significant deter-
minant for cancer metastasis [36, 37]. Moreover, Akt
triggers DOX-induced EMT through Akt/GSK-3β/β-ca-
tenin pathway. Nuclear translocation of β-catenin not
only regulates EMT-associated proteins, which are re-
sponsible for cell migration, but also induces transcrip-
tional upregulation of ZEB1, which in turn regulated
DNA damage repair and DOX-resistance [38]. Recently,
the promotion of Akt phosphorylation could facilitate
EMT, resulting in tumor formation and invasion in AGS
and MKN45 gastric cancer cell lines [39]. Given that Akt
was activated in SGC7901/DOX cells, we are convinced
that the upregulation of Akt signaling pathway best
Xu et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:19 Page 11 of 14
Fig. 7 Effect of DOX and RES on nude mice burdened with SGC7901/DOX xenograpfts. a Nude mice inoculated subcutaneously with SGC7901/
DOX cells were treated with DOX, RES or both for 4 weeks. At the end of the treatment period, mice were sacrificed and tumor specimens
harvested. The tumor volume (V) was determined by measuring the length (a) and width (b) with calipers every week and calculated using the
formula: V (mm3) =1/2ab2. Mean tumor volume for each treatment group is indicated. Results are represented as the mean ± SD of 5 mice per
group (n = 5,***p < 0.001). b Tumor specimens were subjected to immunohistochemical staining for PTEN,Ki67, caspase3 and vimentin. Images
were captured at 400× magnification. The Scale bar represents 50 μm. Mean density of each group (Integrated optical density/Area) was
presented (n = 5, *** p < 0.001; * p < 0.05;NS means not significant, p > 0.05). c A hypothetical model illustrating that RES reverses DOX-induced
EMT and DOX-resistance by modulating PTEN/Akt signaling pathway. This picture was designed by J.X. and Q.Z
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illustrates DOX-induced EMT, cell migration and drug re-
sistance mentioned above. Even though activation of Akt
signaling pathway was maintained by DOX treatment in
SGC7901/DOX cells, caspase-3 mediated apoptosis was
promoted by DOX in spite of caspase-9 inactivation by
Akt. Therefore, DOX could induce SGC7901/DOX cell
apoptosis in an Akt-independent way.
To alleviate the adverse effects of DOX, we took note
of RES, a well-known phytochemical with diverse
health benefits, as a possible supplement for DOX
treatment. RES demonstrated its valid potentials as a
chemosensitizer for DOX in breast cancer cells [40]. In
gastric cancer MGC803 cells, RES was able to induce
cell cycle arrest by targeting PTEN. As a negative regu-
lator of PI3K/Akt pathway which dephosphorylates PIP3,
PTEN has been reported to reverse EMT-mediated drug
resistance [41]. Consistent with our data, an early study
revealed RES is able to suppress cell invasion and the
expression of Snail and N-cadherin and increase that of
E-cadherin, which suggested that RES has an EMT-
inhibitory effect in SGC7901 cells [42]. We discovered
that PTEN expression was enhanced by RES dominantly
and dose-dependently in DOX-resistant SGC7901/DOX
gastric cancer cells. Consequently, PI3K/Akt pathway was
down-regulated, which activated caspase-3 dependent
apoptosis, suppressed colony formation, and more im-
portantly, inhibited EMT, leading to the suppression of
cell migration and the reverse of DOX-resistance of
SGC7901/DOX cells. Similar effects were also con-
firmed in SGC7901/DOX in vivo xenograpft tumor
model.
Conclusions
Our study revealed that Akt aberrant activation-
mediated EMT is the key to the acquisition of DOX-
resistance in SGC7901 gastric cancer cells during long-
term DOX treatment. RES could attenuate the adverse
effects of DOX by activating PTEN and subsequently
modulating Akt pathway activity, thus further promoting
apoptosis and reversing EMT process. In conclusion,
RES serves as a novel solution which can not only syner-
gize DOX in inhibiting the tumor growth, but also
reverse the DOX-resistance and prevent cell migration
via the suppression of EMT in gastric cancer by modu-
lating PTEN/Akt signaling pathway. The DOX-RES
combined treatment provides a promising future for gas-
tric cancer patients with metastasis and drug resistance
tendency.
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